Essais liés6clinical trials
VilleKnoxvillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06782490

Ouvrir le site du centre

Essais cliniques associés

6
MoléculeIndication / populationPhaseNCTTitreStatut
BMS-986368 Myopathies Phase 2 NCT06782490 MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity RECRUITING
Ocrelizumab SEP Phase 3 NCT04544436 MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
Ocrelizumab Co-formulated With rHuPH20 SEP Phase 1 NCT07667322 OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Ocrelizumab Test Formulation SEP Phase 2 NCT07074886 PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04586023 FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING